US EditionClinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal - PressReach
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal - PressReach
CHENGDU, China, April 12, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the treatment of adult patients with advanced triple-negative breast cancer (TNBC) and results from an early Phase I/II clinical study of sac-TMT for the treatment of a…
Clinical research results for Kelun-Biotech’s TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal
CHENGDU, China, April 12, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the treatment of adult patients with advanced triple-negative breast cancer (TNBC) and results from an early Phase I/II clinical […]
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
